Professor Neil John Lloyd Gittoes BSc MB ChB PhD FRCP

Professor Neil John Lloyd Gittoes

Institute of Metabolism and Systems Research
Consultant Endocrinologist and Honorary Professor of Endocrinology

Contact details

0121 627 2384
+44 (0)121 371 6941
Centre for Endocrinology, Diabetes and Metabolism (CEDAM)
3rd Floor, Heritage Building
Queen Elizabeth Hospital
Birmingham, B15 2TH

Professor Neil Gittoes is Consultant Endocrinologist at the Queen Elizabeth Hospital, Birmingham and Honorary Professor of Endocrinology at the University of Birmingham. He is inaugural Head of the Centre of Endocrinology, Diabetes and Metabolism (CEDAM), a partnership organisation across NHS provider organisations and the University of Birmingham aiming to optimise translational research outputs, international education in diabetes, endocrinology and metabolism and foster early careers engagement in clinical and non-clinical areas of these disciplines. Neil is recognised nationally and internationally for his work in metabolic bone diseases including osteoporosis, vitamin D deficiency and disorders of calcium homeostasis. He has co-authored recent international guidance on management of parathyroid diseases and UK guidance on osteoporosis. He has several roles in NHS England and has been responsible for policies supporting the use of endocrine drugs in rare conditions. He has expertise in many facets of peer review and service development and through his roles as Chair of the West Midlands Clinical Senate, has responsibility for clinical quality assurance and dissemination of best practice. 


  • FRCP Royal College of Physicians 2004
  • PhD Molecular Endocrinology, University of Birmingham 2008
  • MRCP Royal College of Physicians 2003
  • MBChB (Honours) Medicine and Surgery, University of Birmingham 1990
  • BSc (Honours) Anatomical Studies, University of Birmingham, 1987


Professor Neil Gittoes leads the metabolic bone diseases unit in Birmingham, and a number of national work streams through the Royal Osteoporosis Society as Chair of the Board of Trustees and as National Clinical Lead for Specialised Endocrinology, NHSEI. Neil is member of the National Osteoporosis Guideline Group (NOGG); he works with NICE and was Clinical Lead for NICE Guideline on Primary Hyperparathyroidism (NG132) and instigated Rapid Evidence Summary for vitamin D in COVID-19 (ES28). He is member and co-chair of the International Taskforce and European PARAT programme on parathyroid disorders. He was honoured by the Royal College of Physicians and made Goulstonian Lecturer for his contributions to clinical research. He has published more than 150 papers, reviews and chapters across endocrinology, focussing on bone and mineral metabolism. His clinical research interests include models of fracture prevention, rare causes of fracture susceptibility and disorders of calcium homeostasis.


  • Gittoes (PI)   09/19   09/2021  NIHR HTA Reference Number: NIHR127550 - The BLAST OFF (Bisphosphonate aLternAtive regimenS for the prevenTion of Osteoporotic Fragility Fractures) Study – “The study looks at how effective different bisphosphonate regimens are compared to Alendronate at preventing fractures, whether the reduction in fracture risk can be achieved at a reasonable financial cost and to establish the acceptability of different approaches to patients”.   £458,682 + £7174 NHS costs
  • Gittoes (PI) 11/2018 , 07/2020, Shire Pharmaceuticals – “A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]”
  • Gittoes (PI), 12/2018, 12/2020, Efficacy and Mechanism Evaluation and Eli Lilly – “Randomised Trial of Teriparatide followed by Zoledronic Acid versus standard care to prevent fractures in adults with Osteogenesis Imperfecta (TOPaZ)” 
  • Gittoes (PI), 12/2018, Kyowa Kirin – “An international, multicentre, prospective, non-interventional observational registry for patients with X-linked hypophosphatemia (XLH)”
  • Greig (PI) and Gittoes 09/2015, 08/2018, National Osteoporosis Society PhD studentship 3 years – “Influence of combined vitamin D supplementation and resistance exercise training on musculoskeletal health in frail older men and women (EXVITD)” £94,160
  • Cooper (PI), Stewart, Eastell, Gittoes*, 10/2015, 09/2017, MRC-Astra Zeneca Co-funded translational research grant for staff and consumables 2 years - “Phase II study of the impact of a selective 11beta-HSD1 inhibitor on biochemical markers”. *Study subsequently moved to University of Leeds. Gittoes currently member of Safety Review Committee.  £311,707
  • Wordsworth (CI), multiple co-Is, 05/2015, NIHR Rare Diseases Translational Research Collaboration & Oxford NIHR Musculoskeletal Biomedical Research Unit - “Rare diseases of the bone, joint and vessels Study (RUDY)”   £112,456
  • Gittoes (PI), 12/2015, Alexion Pharmaceuticals “An observational, longitudinal, prospective, long-term registry of patients with hypophosphatasia”         
  • Hiwot (PI) and Gittoes 12/2012, 11/2015, Shire Pharmaceuticals for post-doctoral fellow 3 years - “Understanding the molecular mechanism of bone disease in patients with Gaucher’s disease”    £195,000
  • Doyle (PI), Gittoes, Tsesmelis, 11/2013, 12/2015, Older Adults Workforce Integration Board, Birmingham and Solihull 2 years “Falls and Fractures Prevention in Care Homes” £171,091
  • Shepstone (CI), Cooper, Gittoes, Harvey, Heawood,  McCloskey, O’Neill, Peters, Torgerson (Co-PIs), 11/2006, 11/2015 (further extension planned)     MRC Health Technology Assessment Grant 7 years + extension “A pragmatic randomised controlled trial of screening for osteoporosis in older women”  Total research £4,280,273 +NHS costs £4,750,985

Other activities

  • Chair of the Board of Trustees, Royal Osteoporosis Society
  • Chair, West Midlands Clinical Senate, NHSE
  • National Clinical Lead, Specialised Commissioning of Endocrine Services, NHSE
  • Medical Vice Chair, West Midlands Committee of the Advisory Committee on Clinical Impact Awards (ACCIA),  DHSC


Bjornsdottir S, Ing S, Mitchell DM, Sikjaer T, Underbjerg L, Hassan-Smith Z, Sfeir J, Gittoes NJ, Clarke L BL. Epidemiology and Financial Burden of Adult Chronic Hypoparathyroidism. J Bone Miner Res. 2022 Dec;37(12):2602-2614. doi: 10.1002/jbmr.4675. Epub 2022 Aug 29. PMID: 36054571

Khan AA, Bilezikian JP, Brandi ML, Clarke BL, Gittoes NJ, Pasieka JL, Rejnmark L, Shoback DM, Potts JT, Guyatt GH, Mannstadt M. Evaluation and Management of Hypoparathyroidism Summary Statement and Guidelines from the Second International Workshop. J Bone Miner Res. 2022 Dec;37(12):2568-2585. doi: 10.1002/jbmr.4691. Epub 2022 Nov 14. PMID: 36054621

Bilezikian JP, Silverberg SJ, Bandeira F, Cetani F, Chandran M, Cusano NE, Ebeling PR, Formenti AM, Frost M, Gosnell J, Lewiecki EM, Singer FR, Gittoes N, Khan AA, Marcocci C, Rejnmark L, Ye Z, Guyatt G, Potts JT. Management of Primary Hyperparathyroidism. J Bone Miner Res. 2022 Nov;37(11):2391-2403. doi: 10.1002/jbmr.4682. Epub 2022 Oct 17. PMID: 36054638

Bastounis A, Langley T, Davis S, Paskins Z, Gittoes N, Leonardi-Bee J, Sahota O. Assessing the Effectiveness of Bisphosphonates for the Prevention of Fragility Fractures: An Updated Systematic Review and Network Meta-Analyses. JBMR Plus. 2022 Mar 25;6(5):e10620. doi: 10.1002/jbm4.10620. eCollection 2022 May. PMID: 35509636

Bollerslev J, Rejnmark L, Zahn A, Heck A, Appelman-Dijkstra NM, Cardoso L, Hannan FM, Cetani F, Sikjær T, Formenti AM, Björnsdottir S, Schalin-Jantti C, Belaya Z, Gibb FW, Lapauw B, Amrein K, Wicke C, Grasemann C, Krebs M, Ryhänen EM, Makay O, Minisola S, Gaujoux S, Bertocchio JP, Hassan-Smith ZK, Linglart A, Winter EM, Kollmann M, Zmierczak HG, Tsourdi E, Pilz S, Siggelkow H, Gittoes NJ, Marcocci C, Kamenicky P. European Expert Consensus on Practical Management of Specific Aspects of Parathyroid Disorders in Adults and in Pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders. Eur J Endocrinol. 2021 Dec 1:EJE-21-1044.R1. doi: 10.1530/EJE-21-1044. Online ahead of print. PMID: 34863037

Davis S, Simpson E, Hamilton J, James MM, Rawdin A, Wong R, Goka E, Gittoes N, Selby P. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. Health Technol Assess. 2020 Jun;24(29):1-314. doi: 10.3310/hta24290. PMID: 32588816 Free PMC article.

Gittoes NJ, Selby P, Davis S. (2020) Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis. Bone. 2020 Jan;130:115081. doi: 10.1016/j.bone.2019.115081. Epub 2019 Oct 15. PMID: 31626995

Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M, Strong M, Selby P, Gittoes N. Corrigendum: A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technology Assessment. 2018 Mar;20(78):407-424. doi: 10.3310/hta20780-c201803.

Turner DA, Fong Soe Khioe R, Shepstone L, Lenaghan E, Cooper C, Gittoes NJL, Harvey N, Holland R, Howe A, McCloskey E, O’Neill T, Torgerson D, Fordham R, and the SCOOP Study Team. The cost-effectiveness of screening in the community to reduce osteoporotic fractures in older women: economic evaluation of the SCOOP study. J Bone Miner Res. 2018 Feb 22. doi: 10.1002/jbmr.3381. [Epub ahead of print] PMID: 29470854

Shepstone L, Lenaghan E, Cooper C, Clarke S, Fong-Soe-Khioe R, Fordham R, Gittoes NJ, Harvey I, Harvey N, Heawood A, Holland R, Howe A, Kanis J, Marshall T, O’Neill T, Peters T, Redmond N, Torgerson D, Turner D, McCloskey E; for the SCOOP Study Team* Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet. 2018 Feb 24;391(10122):741-747. doi: 10.1016/S0140-6736(17)32640-5. Epub 2017 Dec 16 PMID: 29254858


Metabolic bone disease, osteoporosis, vitamin D, Paget’s disease, primary hyperparathyroidism, hypoparathyroidism, calcium, hypercalcaemia, hypocalcaemia

Media experience

Radio and TV


Metabolic bone disease, osteoporosis, vitamin D, Paget’s disease, primary hyperparathyroidism, hypoparathyroidism, calcium, hypercalcaemia, hypocalcaemia

Policy experience